Alexion Pharma Poland sp. z o.o.
Research and experimental development on biotechnology
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2022-03-17
Share capital
5,000.00 PLN
Registered address
ul. Postępu 14, 02-676 Warszawa, Poland
Electronic delivery address
AE:PL-59462-48907-UWHTS-30
Financials
Revenue history (in k)
From the notes
| Profit allocation | Retained in reserve capital |
Filing timeliness
2 of 4 financial statements were filed late (the longest delay 628 days for 2022).
- 202502/07/2026
- 202410/07/2025
- 202303/04/2025
- 202203/04/2025
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 4.03mMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD 117.28kMedianUSD -1.27kAverageUSD -92.87k
Operating costs
This companyUSD 3.72mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 1.28mMedianUSD 134.71kAverageUSD 3.04m
Industry
Authorized Representatives
Agata Wiesiołek age 47 – Management Board Member
Beata Purzycka age 52 – Management Board Member
Manner of representation
Each member of the management board has the right to represent the company independently
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Alexion Holding B.v. | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Sanctions and PEP
Sanctions
No matches (EU, UN, US, UK, MSWiA, World Bank)
PEP
No matches
Bank accounts
Registered as a VAT taxpayer on 2023-08-08.
62 1030 1335 0000 0008 2368 4500
92 1030 1508 0000 0008 2368 4001
22 1030 1508 0000 0008 2368 4000
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Famicordtx S.A. | $1,365,068.41 | famicordtx.com | ||
| Orphinic Scientific S.A. | $518,429.97 | orphinic.com | ||
| Proper Medical Writing sp. z o.o. | $464,661.64 | propermedicalwriting.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeutics sp. z o.o. | $304,662.00 | explorna.com | ||
| Frontline Biosciences S.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelab sp. z o.o. | $128,365.55 | aicorelab.com | ||
| Modica P.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticals sp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD Pharmaceuticals S.A. | $87,561.70 | wpdpharmaceuticals.pl |
Change history
| Date | Event | |
|---|---|---|
| 2022-09-22 | Address change (Ul. Towarowa 28, 00-839, Warszawa → Ul. Postępu 14, 02-676, Warszawa) | |
| 2022-09-22 | Name change (Lavyport Investments → Alexion Pharma Poland) | |
| 2022-09-22 | PKD change (Removed: 9 codes; Added: 7 codes) | |
| 2022-03-17 | Entered in the register |
FAQ
The main business activity of Alexion Pharma Poland focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on March 17, 2022.
The headquarters is located at: ul. Postępu 14, 02-676 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company's revenue reached $317,789.
Yes, the company recorded a net profit of $18,765 in 2024.
The largest operating cost category falls under employee remuneration. This category amounted to $285,861 in 2024, representing 98% of all operating expenses.
Last updated: 2026-10-07